BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 118 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.75 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $326,706 | +8.5% | 52,865 | -10.8% | 0.16% | 0.0% |
Q1 2024 | $301,026 | -0.9% | 59,257 | +16.8% | 0.16% | -17.1% |
Q4 2023 | $303,879 | +12.0% | 50,731 | +32.4% | 0.19% | +17.0% |
Q3 2023 | $271,313 | -11.0% | 38,321 | -11.5% | 0.16% | -8.8% |
Q2 2023 | $304,677 | +32.5% | 43,278 | +57.0% | 0.18% | +43.7% |
Q1 2023 | $229,942 | -26.1% | 27,571 | +1.8% | 0.13% | -22.2% |
Q4 2022 | $310,947 | -1.0% | 27,086 | +8.7% | 0.16% | +29.6% |
Q3 2022 | $314,000 | +20.8% | 24,920 | +1.5% | 0.12% | +30.2% |
Q2 2022 | $260,000 | -50.9% | 24,556 | -24.5% | 0.10% | -59.5% |
Q1 2022 | $529,000 | +17.3% | 32,542 | 0.0% | 0.24% | +39.4% |
Q4 2021 | $451,000 | +11.6% | 32,542 | +15.8% | 0.17% | -4.5% |
Q3 2021 | $404,000 | -16.7% | 28,090 | -8.4% | 0.18% | -10.6% |
Q2 2021 | $485,000 | +35.1% | 30,669 | -13.2% | 0.20% | +30.9% |
Q1 2021 | $359,000 | +38.6% | 35,331 | +1.8% | 0.15% | +42.1% |
Q4 2020 | $259,000 | +4.9% | 34,707 | -51.7% | 0.11% | -17.7% |
Q3 2020 | $247,000 | -36.5% | 71,844 | -12.0% | 0.13% | -29.3% |
Q2 2020 | $389,000 | +60.7% | 81,644 | -32.6% | 0.18% | +84.0% |
Q1 2020 | $242,000 | -49.5% | 121,058 | -12.7% | 0.10% | +28.2% |
Q4 2019 | $479,000 | +123.8% | 138,719 | +86.1% | 0.08% | +81.4% |
Q3 2019 | $214,000 | -28.2% | 74,533 | -5.3% | 0.04% | -31.7% |
Q2 2019 | $298,000 | +16.9% | 78,684 | +151.6% | 0.06% | -88.4% |
Q1 2019 | $255,000 | -10.5% | 31,277 | -11.4% | 0.54% | +1008.2% |
Q4 2018 | $285,000 | -55.3% | 35,300 | -57.7% | 0.05% | -25.8% |
Q3 2018 | $637,000 | -22.3% | 83,470 | -41.7% | 0.07% | -90.9% |
Q2 2018 | $820,000 | +11.6% | 143,132 | -7.1% | 0.72% | +13.6% |
Q1 2018 | $735,000 | +110.6% | 154,147 | +116.9% | 0.64% | +45.7% |
Q4 2017 | $349,000 | +17.1% | 71,081 | +25.0% | 0.44% | +995.0% |
Q3 2017 | $298,000 | +3.8% | 56,873 | +10.1% | 0.04% | -7.0% |
Q2 2017 | $287,000 | -32.8% | 51,671 | +1.5% | 0.04% | -43.4% |
Q1 2017 | $427,000 | +46.7% | 50,888 | +10.6% | 0.08% | -12.6% |
Q4 2016 | $291,000 | -22.2% | 46,010 | -45.8% | 0.09% | -51.9% |
Q3 2016 | $374,000 | +55.2% | 84,907 | 0.0% | 0.18% | +1.1% |
Q2 2016 | $241,000 | +225.7% | 84,907 | +223.5% | 0.18% | +75.5% |
Q1 2016 | $74,000 | – | 26,246 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |